Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2023 > Vol 4, №10 (2023) > Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea

Anna V. Berdnikova, Natalya B. Kadymova, Nina V. Latysheva, Margarita V. Naprienko, Elena G. Filatova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Background. Menstrual related migraine (MRM) occurs in 60% of women with migraine. These attacks are characterized by high intensity and poor response to abortive and prophylactic treatment. Hormonal therapy is one of the main treatment methods, but it has a large number of limitations. Increase in the CGRP level triggered by a decrease of estrogen levels is one of the basic mechanisms of MRM. It is of interest therefore to study the impact of anti-CGRP monoclonal antibodies (mAbs) in MRM. In addition, many patients have severe pelvic pain in the perimenstrual period (algodysmenorrhea). Algodysmenorrhea is associated with other chronic pain syndromes including migraine. Therefore, it is interesting to study the impact of anti-CGRP monoclonal antibodies on algodysmenorrhea. 
Material and methods. We recruited 64 women with migraine (episodic and chronic) over 18 years of age with regular menstrual cycle. 21 patients were diagnosed with MRM according to the International Classification of Headache Disorders, 3rd edition. Demographic data, migraine history, menstrual cycle characteristics and algodysmenorrhea symptoms were collected. Patients were treated with erenumab or fremanezumab for 3 months and followed up monthly with headache diaries. 
Results. After 3 months of treatment, the intensity of menstrual migraine attacks and algodysmenorrhea decreased by 50% or more (p=0,03* and p=0,045*, accordingly). There was a significant decrease in the total amount of headache days in MRM patients. 
Conclusion. Anti-CGRP mAbs are effective in MRM and algodysmenorrhea. Further studies are necessary.
Key words: migraine, monoclonal antibodies, Erenumab, Fremanezumab, CGRP, menstrual-related migraine, algodysmenorrhea.

About the Author

Anna V. Berdnikova 1 , Natalya B. Kadymova 2 , Nina V. Latysheva 1 , Margarita V. Naprienko 1 , Elena G. Filatova 1

1 Alexander Vein Headache Clinic, Moscow, Russia; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

2 Alexander Vein Headache Clinic, Moscow, Russia

References

1. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2017; 390: 1211–859. DOI: 10.1016/S0140-6736(17)32154-2
2. Stewart WF, Wood C, Reed ML et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008; 28 (11): 1170–78. DOI: 10.1111/j.1468-2982.2008.01666.x
3. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017; 16 (1): 76–87. DOI: 10.1016/S1474-4422(16)30293-9
4. Buse D, Loder E, Gorman J et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study. J Head Face Pain. 2013; 53: 1278–99. DOI: 10.1111/head.12150
5. Pavlović JM, Allshouse AA, Santoro NF et al. Sex hormones in women with and without migraine: Evidence of migraine-specific hormone profiles. Neurology. 2016; 87 (1): 49–56. DOI: 10.1212/WNL. 0000000000002798
6. van Oosterhout WPJ, Schoonman GG, van Zwet EW et al. Female sex hormones in men with migraine. Neurology. 2018; 91 (4): e374–e381. DOI: 10.1212/WNL.0000000000005855
7. Gupta S, Villalón CM, Mehrotra S et al. Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. J Head Face Pain. 2007; 47 (2): 225–35. DOI: 10.1111/j.1526-4610.2006.00526.x
8. Ornello R, De Matteis E, Di Felice C et al. Acute and Preventive Management of Migraine during Menstruation and Menopause. J Clin Med. 2021; 10 (11): 2263. DOI: 10.3390/jcm10112263
9. Wang D, Zhao J, Wang J et al. Deficiency of female sex hormones augments PGE2 and CGRP levels within midbrain periaqueductal gray.
J Neurol Sci. 2014; 346: 107–11. DOI: 10.1016/j.jns.2014.08.002
10. Li R, Li B, Kreher DA et al. Association between dysmenorrhea and chronic pain: a systematic review and meta-analysis of population-based studies. Am J Obstet Gynecol. 2020; 223 (3): 350–71. DOI: 10.1016/j.ajog.2020.03.002
11. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders (3rd edition). Cephalalgia. 2018; 38: 1–211. DOI: 10.1177/0333102417738202
12. McKenna KA, Fogleman CD. Dysmenorrhea. Am Fam Physician. 2021; 104 (2): 164–70.
13. Cupini LM, Corbelli I, Sarchelli P. Menstrual migraine: what it is and does it matter? J Neurol. 2020; 268 (7): 2355–63. DOI: 10.1007/ s00415-020-09726-2
14. Ibrahimi K, Danser AHJ, Villalón CM, et al. A. Influence of varying estrogen levels on trigeminal CGRP release in healthy women.
J Headache Pain. 2013; 14 (Suppl. 1): 123. DOI: 10.1186/1129-2377-14-S1-P123
15. Ibrahimi K, Vermeersch S, Frederiks P et al. The influence of migraine and female hormones on capsaicin-induced dermal blood flow. Cephalalgia. 2017; 37: 1164–72. DOI: 10.1177/0333102416668659
16. Ibrahimi K, van Oosterhout WP, van Dorp W, et al. Reduced trigeminovascular cyclicity in patients with menstrually related migraine. Neurology. 2015; 84: 125–31. DOI: 10.1212/WNL.0000000000001142
17. Silvestro M, Orologio I, Bonavita S et al. Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience. Pain Ther. 2021; 10 (2): 1203–14. DOI: 10.1007/s40122-021-00273-w

For citation:Berdnikova A.V., Kadymova N.B., Latysheva N.V., Naprienko M.V., Filatova E.G. Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea. Clinical review for general practice. 2023; 4 (10): 90–94 (In Russ.). DOI: 10.47407/kr2023.4.10.00347


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru